Literature DB >> 3768961

Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells.

J S Tuttleman, C Pourcel, J Summers.   

Abstract

Covalently closed circular (CCC) double-stranded DNA believed to be the transcriptional template for duck hepatitis B virus (DHBV) is amplified in aging primary cultures of hepatocytes from congenitally infected ducklings. Analysis of 5-bromodeoxyuridine-labeled heavy/light CCC DNA shows that the relaxed circular DNA synthesized in the cytoplasm by reverse transcription is the predominant precursor to the amplified pool of nuclear viral CCC DNA. In vitro infection of uninfected hepatocyte cultures with DHBV demonstrates that a similar 50-fold amplification of CCC DNA occurs during an early stage in the infection before virus production. This amplification allows the establishment of a pool of transcriptional templates in the cell without the need for semiconservative replication or multiple rounds of infection. This process may account for the ability of hepadnavirus-infected cells persistently to produce virus particles in the absence of stable integration of viral DNA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3768961     DOI: 10.1016/0092-8674(86)90602-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  265 in total

1.  The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen.

Authors:  T T Yuan; G K Sahu; W E Whitehead; R Greenberg; C Shih
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

3.  Low dynamic state of viral competition in a chronic avian hepadnavirus infection.

Authors:  Y Y Zhang; J Summers
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

4.  Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.

Authors:  W E Delaney; T G Miller; H C Isom
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.

Authors:  William R Addison; Kathie-Anne Walters; Winnie W S Wong; John S Wilson; Danuta Madej; Lawrence D Jewell; D Lorne J Tyrrell
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor.

Authors:  W Yang; J Summers
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.

Authors:  W E Delaney; R Edwards; D Colledge; T Shaw; J Torresi; T G Miller; H C Isom; C T Bock; M P Manns; C Trautwein; S Locarnini
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

8.  Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy.

Authors:  L Luckenbaugh; K M Kitrinos; W E Delaney; J Hu
Journal:  J Viral Hepat       Date:  2014-11-14       Impact factor: 3.728

9.  Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections.

Authors:  T Zhou; J T Guo; F A Nunes; K L Molnar-Kimber; J M Wilson; C E Aldrich; J Saputelli; S Litwin; L D Condreay; C Seeger; W S Mason
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

10.  A secondary structure that contains the 5' and 3' splice sites suppresses splicing of duck hepatitis B virus pregenomic RNA.

Authors:  Daniel D Loeb; Amanda A Mack; Ru Tian
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.